Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)
Phase 4
Completed
- Conditions
- Bacterial Infection
- Registration Number
- NCT00254696
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
* To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.
* To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre and post intervention in the selected medical centers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 710
Inclusion Criteria
- Patients admitted or transferred to the ICU/pulmonary/hematology units.
- Patients of either sex, 18 years of age or older
Exclusion Criteria
- Pregnant and nursing women. Female of childbearing potential without using any birth control methods. Female of childbearing potential using oral contraceptives during study period. (Note: penicillin and beta-lactamase inhibitors may prevent oral contraceptives from working properly, increasing the chance of pregnancy).
- Patients who have the contraindications of using Tazocin (pipercillin/tazobactam)
Other exclusions apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months)
- Secondary Outcome Measures
Name Time Method Infection rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain piperacillin/tazobactam's efficacy against ESBL-producing E. coli and K. pneumoniae?
How does piperacillin/tazobactam compare to carbapenems in controlling ESBL infections in clinical settings?
Are there specific biomarkers that identify patients most likely to benefit from piperacillin/tazobactam in ESBL infections?
What adverse events are associated with piperacillin/tazobactam use in ESBL-infected patients and how are they managed?
What combination therapies or alternative antibiotics are being explored for ESBL-producing Enterobacteriaceae infections alongside piperacillin/tazobactam?